Open Payments

RAJESH BEHL

Type
Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
Where
BERKELEY, CA
NPI
1104844174
Received
$583,960 in 777 records, 2019 to 2025 ($583,925 general, $35 research)
As principal investigator
$548,941 of research payments to others in 79 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment342$164,983
2024General payment61$56,386
2023General payment58$59,789
2023Research payment1$35
2022General payment123$153,919
2021General payment66$79,546
2020General payment26$19,881
2019General payment100$49,418

By company

CompanyRecordsAmountYears
Karyopharm Therapeutics Inc.98$165,2252020–2025
Takeda Pharmaceuticals U.S.A., Inc.111$103,7792019–2025
ABBVIE INC.85$69,5322019–2025
Janssen Biotech, Inc.75$42,3452019–2025
GlaxoSmithKline, LLC.21$28,7652021–2025
ADC THERAPEUTICS AMERICA, INC.25$24,6402021–2025
Novartis Pharmaceuticals Corporation28$23,9702019–2025
Incyte Corporation28$19,8632021–2025
Genmab U.S., Inc.28$17,3282023–2025
E.R. Squibb & Sons, L.L.C.29$13,8662019–2025
AstraZeneca Pharmaceuticals LP27$11,1822019–2025
Kite Pharma, Inc.19$11,0712020–2025
Celgene Corporation20$8,2552019–2025
JAZZ PHARMACEUTICALS INC.13$7,1842019–2025
BeiGene USA, Inc.9$7,1162020–2025
PFIZER INC.29$5,8412019–2025
Syndax Pharmaceuticals, Inc.6$4,3862025
Amgen Inc.8$4,2522019–2024
Gilead Sciences, Inc.8$4,0592023–2025
Invivyd Inc2$2,8382025
Daiichi Sankyo Inc.6$2,0322020–2025
Janssen Scientific Affairs, LLC1$1,3622023
Rigel Pharmaceuticals, Inc.2$1,0222020–2025
Adaptive Biotechnologies Corporation1$1,0002021
BeiGene, Ltd.1$4502020
Merck Sharp & Dohme LLC17$4342019–2025
ARRAY BIOPHARMA INC11$2652025
Exelixis Inc.3$1362019–2025
Agios Pharmaceuticals, Inc.5$1342019–2025
SEAGEN INC.3$1132019–2023
Integra LifeSciences Corporation2$1122025
Boehringer Ingelheim Pharmaceuticals, Inc.4$1002019–2025
Eisai Inc.4$942019–2025
GENZYME CORPORATION3$862025
PROGENICS PHARMACEUTICALS, INC.1$852024
Pharmacyclics LLC, an AbbVie Company4$812019–2023
Iovance Biotherapeutics, Inc.3$772025
BeOne Medicines USA, Inc.3$682025
Astellas Pharma US Inc3$632019–2025
SpringWorks Therapeutics, Inc.2$482025
Alexion Pharmaceuticals, Inc.2$482020–2025
TAIHO ONCOLOGY, INC.2$422019
Janssen Pharmaceuticals, Inc3$392019–2025
SOBI, INC1$362025
Ipsen Biopharmaceuticals, Inc1$342025
Tempus AI, Inc2$332025
Coherus Oncology, Inc.1$322025
Spectrum Pharmaceuticals Inc.1$302025
PharmaEssentia USA Corporation1$292025
Genentech USA, Inc.1$282025

By nature of payment

NatureRecordsAmount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v74$206,815
Honoraria45$155,651
Consulting Fee62$144,683
Travel and Lodging150$57,882
Food and Beverage426$18,451
Education19$441
Research payment1$35

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-24Syndax Pharmaceuticals, Inc.$3,127Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGY2025
2025-12-22Legend Biotech USA Inc.$24Food and BeverageIn-kind items and servicesCARVYKTI Biological, Oncology2025
2025-12-21Syndax Pharmaceuticals, Inc.$21Food and BeverageIn-kind items and services2025
2025-12-18ABBVIE INC.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVENCLEXTA Drug, ONCOLOGY2025
2025-12-18ABBVIE INC.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEPKINLY Drug, ONCOLOGY2025
2025-12-18Syndax Pharmaceuticals, Inc.$1,042Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGY2025
2025-12-18E.R. Squibb & Sons, L.L.C.$30Food and BeverageCash or cash equivalentREBLOZYL Biological, Hematology2025
2025-12-18E.R. Squibb & Sons, L.L.C.$1Food and BeverageCash or cash equivalentREBLOZYL Biological, Hematology2025
2025-12-17BeOne Medicines USA, Inc.$24Food and BeverageIn-kind items and servicesBRUKINSA Drug, Oncology2025
2025-12-11ABBVIE INC.$164Travel and LodgingIn-kind items and servicesEPKINLY Drug, ONCOLOGY2025
2025-12-11ABBVIE INC.$41Food and BeverageIn-kind items and servicesEPKINLY Drug, ONCOLOGY2025
2025-12-11AstraZeneca Pharmaceuticals LP$28Food and BeverageIn-kind items and servicesTAGRISSO Drug, Oncology2025
2025-12-10Karyopharm Therapeutics Inc.$1,550HonorariaCash or cash equivalentXPOVIO Drug, Oncology2025
2025-12-09Syndax Pharmaceuticals, Inc.$147Food and BeverageIn-kind items and servicesREVUFORJ Drug, HEMATOLOGY-ONCOLOGY2025
2025-12-08Kite Pharma, Inc.$26Food and BeverageIn-kind items and servicesYescarta Drug, CELLT2025
2025-12-04ABBVIE INC.$251Travel and LodgingIn-kind items and servicesVENCLEXTA Drug, ONCOLOGY2025
2025-12-04ABBVIE INC.$124Food and BeverageIn-kind items and servicesVENCLEXTA Drug, ONCOLOGY2025
2025-12-04E.R. Squibb & Sons, L.L.C.$32Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2025
2025-12-03PFIZER INC.$34Food and BeverageIn-kind items and servicesIBRANCE Drug, ONCOLOGY2025
2025-12-03Takeda Pharmaceuticals U.S.A., Inc.$21Food and BeverageIn-kind items and servicesICLUSIG Drug, ONCOLOGY2025
2025-12-03Takeda Pharmaceuticals U.S.A., Inc.$1Food and BeverageIn-kind items and servicesNINLARO Drug, ONCOLOGY2025
2025-12-02JAZZ PHARMACEUTICALS INC.$37Food and BeverageIn-kind items and servicesZEPZELCA Drug, HEMATOLOGY/ONCOLOGY2025
2025-12-01Agios Pharmaceuticals, Inc.$23Food and BeverageIn-kind items and servicesPYRUKYND Drug, Genetically Defined Disease2025
2025-11-26ABBVIE INC.$0Food and BeverageIn-kind items and servicesVENCLEXTA Drug, ONCOLOGY2025
2025-11-25ABBVIE INC.$25Food and BeverageIn-kind items and servicesEPKINLY Drug, ONCOLOGY2025
2025-11-20ABBVIE INC.$19Food and BeverageIn-kind items and servicesVENCLEXTA Drug, ONCOLOGY2025
2025-11-19GENZYME CORPORATION$25Food and BeverageIn-kind items and servicesSARCLISA Biological, Oncology2025
2025-11-18ARRAY BIOPHARMA INC$24Food and BeverageIn-kind items and servicesBRAFTOVI Drug, ONCOLOGY2025
2025-11-17Incyte Corporation$24Food and BeverageCash or cash equivalentZYNYZ Drug, Oncology2025
2025-11-13Merck Sharp & Dohme LLC$31Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-11-12Janssen Biotech, Inc.$53Food and BeverageIn-kind items and servicesDARZALEX Biological, Oncology2025
2025-11-11Takeda Pharmaceuticals U.S.A., Inc.$21Food and BeverageIn-kind items and servicesICLUSIG Drug, ONCOLOGY2025
2025-11-11PFIZER INC.$20Food and BeverageIn-kind items and servicesXTANDI Drug, ONCOLOGY2025
2025-11-11Takeda Pharmaceuticals U.S.A., Inc.$1Food and BeverageIn-kind items and servicesNINLARO Drug, ONCOLOGY2025
2025-11-08Genmab U.S., Inc.$1,950Consulting FeeCash or cash equivalentEpkinly Drug, Oncology2025
2025-11-08Genmab U.S., Inc.$102Food and BeverageIn-kind items and servicesEpkinly Drug, Oncology2025
2025-11-08Genmab U.S., Inc.$41Food and BeverageIn-kind items and servicesEpkinly Drug, Oncology2025
2025-11-08Genmab U.S., Inc.$21Travel and LodgingCash or cash equivalentEpkinly Drug, Oncology2025
2025-11-06Merck Sharp & Dohme LLC$30Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-11-05Janssen Biotech, Inc.$226Travel and LodgingCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-11-05GlaxoSmithKline, LLC.$33Food and BeverageIn-kind items and servicesJEMPERLI Biological, ONCOLOGY2025
2025-11-05E.R. Squibb & Sons, L.L.C.$32Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2025
2025-11-05Invivyd Inc$20Food and BeverageIn-kind items and servicesPEMGARDA Biological, INFECTIOUS DISEASE2025
2025-11-04E.R. Squibb & Sons, L.L.C.$21Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2025
2025-11-03SOBI, INC$36Food and BeverageIn-kind items and servicesVonjo Drug, Hematology/Oncology2025
2025-10-30Karyopharm Therapeutics Inc.$3,875HonorariaCash or cash equivalentXPOVIO Drug, Oncology2025
2025-10-30Karyopharm Therapeutics Inc.$122Food and BeverageIn-kind items and servicesXPOVIO Drug, Oncology2025
2025-10-30PFIZER INC.$35Food and BeverageIn-kind items and servicesPADCEV Biological, ONCOLOGY2025
2025-10-29Incyte Corporation$2,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMonjuvi Drug, Oncology2025
2025-10-29Genmab U.S., Inc.$600Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpkinly Drug, Oncology2025
2025-10-29Takeda Pharmaceuticals U.S.A., Inc.$30Food and BeverageIn-kind items and servicesICLUSIG Drug, ONCOLOGY2025
2025-10-29Takeda Pharmaceuticals U.S.A., Inc.$1Food and BeverageIn-kind items and servicesNINLARO Drug, ONCOLOGY2025
2025-10-27Merck Sharp & Dohme LLC$25Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-10-27Tempus AI, Inc$18Food and BeverageIn-kind items and servicesXT CDX Device, ONCOLOGY2025
2025-10-23Janssen Biotech, Inc.$2,860Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-10-23Incyte Corporation$124Food and BeverageCash or cash equivalentMonjuvi Drug, Oncology2025
2025-10-23Janssen Biotech, Inc.$36Food and BeverageIn-kind items and servicesERLEADA Drug, Oncology2025
2025-10-23AstraZeneca Pharmaceuticals LP$21Food and BeverageIn-kind items and servicesENHERTU Biological, Oncology2025
2025-10-23Incyte Corporation$13Travel and LodgingCash or cash equivalentMonjuvi Drug, Oncology2025
2025-10-22Janssen Biotech, Inc.$108Food and BeverageIn-kind items and servicesRYBREVANT Drug, Oncology2025
2025-10-21ARRAY BIOPHARMA INC$35Food and BeverageIn-kind items and servicesLORBRENA Drug, ONCOLOGY2025
2025-10-20Merck Sharp & Dohme LLC$30Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-10-17Janssen Biotech, Inc.$880Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-10-16Janssen Biotech, Inc.$3,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-10-16Janssen Biotech, Inc.$234Travel and LodgingCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-10-16Ipsen Biopharmaceuticals, Inc$34Food and BeverageIn-kind items and servicesOnivyde Drug, Oncology2025
2025-10-14Janssen Biotech, Inc.$47Food and BeverageIn-kind items and servicesDARZALEX Drug, Oncology2025
2025-10-10ABBVIE INC.$2,100Consulting FeeCash or cash equivalentVENCLEXTA Drug, ONCOLOGY2025
2025-10-10Celgene Corporation$31Food and BeverageCash or cash equivalentREBLOZYL Biological, Hematology2025
2025-10-10Celgene Corporation$0Food and BeverageCash or cash equivalentREBLOZYL Biological, Hematology2025
2025-10-09Janssen Biotech, Inc.$115Food and BeverageIn-kind items and servicesRYBREVANT Drug, Oncology2025
2025-10-08EMD Serono, Inc.$21Food and BeverageCash or cash equivalent2025
2025-10-07Gilead Sciences, Inc.$24Food and BeverageIn-kind items and servicesTrodelvy Drug, ONC2025
2025-10-06E.R. Squibb & Sons, L.L.C.$18Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2025
2025-10-01ABBVIE INC.$3,600Consulting FeeCash or cash equivalentEPKINLY Drug, ONCOLOGY2025
2025-10-01ABBVIE INC.$778Travel and LodgingIn-kind items and servicesEPKINLY Drug, ONCOLOGY2025
2025-10-01ABBVIE INC.$275Travel and LodgingIn-kind items and servicesEPKINLY Drug, ONCOLOGY2025
2025-10-01ABBVIE INC.$250Travel and LodgingIn-kind items and servicesEPKINLY Drug, ONCOLOGY2025
2025-10-01Boehringer Ingelheim Pharmaceuticals, Inc.$23Food and BeverageIn-kind items and services2025
2025-09-29Eisai Inc.$23Food and BeverageIn-kind items and servicesLenvima Drug, Oncology2025
2025-09-25Deciphera Pharmaceuticals Inc.$21Food and BeverageIn-kind items and servicesQINLOCK Drug, ONCOLOGY2025
2025-09-24Incyte Corporation$2,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMonjuvi Drug, Oncology2025
2025-09-22GENZYME CORPORATION$38Food and BeverageIn-kind items and servicesWAYRILZ Drug, Immunology2025
2025-09-18ABBVIE INC.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVENCLEXTA Drug, ONCOLOGY2025
2025-09-18Incyte Corporation$197Travel and LodgingCash or cash equivalentMonjuvi Drug, Oncology2025
2025-09-18Incyte Corporation$73Food and BeverageCash or cash equivalentMonjuvi Drug, Oncology2025
2025-09-17Kite Pharma, Inc.$29Food and BeverageIn-kind items and servicesYescarta Drug, CELLT2025
2025-09-17BeOne Medicines USA, Inc.$24Food and BeverageIn-kind items and servicesBRUKINSA Drug, Oncology2025
2025-09-15Genmab U.S., Inc.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpkinly Drug, Oncology2025
2025-09-15Fennec Pharmaceuticals, Inc.$25Food and BeverageIn-kind items and servicesFyarro Drug, Cancer2025
2025-09-15AstraZeneca Pharmaceuticals LP$23Food and BeverageIn-kind items and servicesIMFINZI Biological, Oncology2025
2025-09-12Takeda Pharmaceuticals U.S.A., Inc.$22Food and BeverageIn-kind items and servicesFRUZAQLA Drug, ONCOLOGY2025
2025-09-11E.R. Squibb & Sons, L.L.C.$575Consulting FeeCash or cash equivalent2025
2025-09-11Celgene Corporation$22Food and BeverageCash or cash equivalentREBLOZYL Biological, Hematology2025
2025-09-10ABBVIE INC.$125Food and BeverageIn-kind items and servicesVENCLEXTA Drug, ONCOLOGY2025
2025-09-10Takeda Pharmaceuticals U.S.A., Inc.$30Food and BeverageIn-kind items and servicesICLUSIG Drug, ONCOLOGY2025
2025-09-10ABBVIE INC.$29Travel and LodgingIn-kind items and servicesVENCLEXTA Drug, ONCOLOGY2025
2025-09-10Alexion Pharmaceuticals, Inc.$27Food and BeverageIn-kind items and servicesULTOMIRIS Biological, Rare Disease2025
2025-09-10Takeda Pharmaceuticals U.S.A., Inc.$1Food and BeverageIn-kind items and servicesNINLARO Drug, ONCOLOGY2025
2025-09-09Genmab U.S., Inc.$84Travel and LodgingCash or cash equivalentEpkinly Drug, Oncology2025
2025-09-08E.R. Squibb & Sons, L.L.C.$20Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2025
2025-09-05ABBVIE INC.$115Food and BeverageIn-kind items and servicesEPKINLY Drug, ONCOLOGY2025
2025-09-05ABBVIE INC.$14Food and BeverageIn-kind items and servicesEPKINLY Drug, ONCOLOGY2025
2025-09-04Janssen Biotech, Inc.$33Food and BeverageIn-kind items and servicesDARZALEX Biological, Oncology2025
2025-09-03Tempus AI, Inc$15Food and BeverageIn-kind items and servicesXT CDX Device, ONCOLOGY2025
2025-08-29Invivyd Inc$2,817Consulting FeeCash or cash equivalentPEMGARDA Biological, INFECTIOUS DISEASE2025
2025-08-27E.R. Squibb & Sons, L.L.C.$22Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2025
2025-08-27ADC THERAPEUTICS AMERICA, INC.$21Food and BeverageCash or cash equivalentZYNLONTA Drug, ONCOLOGY2025
2025-08-26JAZZ PHARMACEUTICALS INC.$34Food and BeverageIn-kind items and servicesZEPZELCA Drug, HEMATOLOGY/ONCOLOGY2025
2025-08-25Celgene Corporation$25Food and BeverageCash or cash equivalentREBLOZYL Biological, Hematology2025
2025-08-22E.R. Squibb & Sons, L.L.C.$4,025Consulting FeeCash or cash equivalent2025
2025-08-22ABBVIE INC.$1,200Consulting FeeCash or cash equivalentVENCLEXTA Drug, ONCOLOGY2025
2025-08-22AstraZeneca Pharmaceuticals LP$27Food and BeverageIn-kind items and servicesIMFINZI Biological, Oncology2025
2025-08-21Janssen Biotech, Inc.$880Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-08-21Takeda Pharmaceuticals U.S.A., Inc.$26Food and BeverageIn-kind items and servicesICLUSIG Drug, ONCOLOGY2025
2025-08-20Syndax Pharmaceuticals, Inc.$21Food and BeverageIn-kind items and services2025
2025-08-19ARRAY BIOPHARMA INC$31Food and BeverageIn-kind items and servicesBRAFTOVI Drug, ONCOLOGY2025
2025-08-18Janssen Biotech, Inc.$32Food and BeverageIn-kind items and servicesCARVYKTI Drug, Oncology2025
2025-08-18Janssen Pharmaceuticals, Inc$15EducationIn-kind items and services2025
2025-08-18Janssen Pharmaceuticals, Inc$8EducationIn-kind items and services2025
2025-08-15Janssen Biotech, Inc.$3,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-08-15Janssen Biotech, Inc.$902Travel and LodgingIn-kind items and servicesRYBREVANT Drug, Oncology2025
2025-08-15Janssen Biotech, Inc.$49Travel and LodgingIn-kind items and servicesRYBREVANT Drug, Oncology2025
2025-08-14Janssen Biotech, Inc.$368Travel and LodgingIn-kind items and servicesRYBREVANT Drug, Oncology2025
2025-08-14Incyte Corporation$24Food and BeverageCash or cash equivalentMONJUVI Drug, Oncology2025
2025-08-13Janssen Biotech, Inc.$121Food and BeverageIn-kind items and servicesRYBREVANT Drug, Oncology2025
2025-08-12Incyte Corporation$27Food and BeverageCash or cash equivalentJAKAFI Drug, Hematology/Oncology2025
2025-08-11Janssen Biotech, Inc.$5Travel and LodgingIn-kind items and servicesRYBREVANT Drug, Oncology2025
2025-08-08Janssen Biotech, Inc.$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-08-05AstraZeneca Pharmaceuticals LP$25Food and BeverageIn-kind items and servicesLYNPARZA Drug, Oncology2025
2025-08-04Daiichi Sankyo Inc.$28Food and BeverageIn-kind items and servicesDATROWAY Drug, ONCOLOGY2025
2025-08-01Genmab U.S., Inc.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentEpkinly Drug, Oncology2025
2025-08-01Janssen Biotech, Inc.$2,860Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-07-31Genmab U.S., Inc.$124Food and BeverageIn-kind items and servicesEpkinly Drug, Oncology2025
2025-07-31Iovance Biotherapeutics, Inc.$22Food and BeverageCash or cash equivalentAmtagvi Drug, Oncology2025
2025-07-30Janssen Biotech, Inc.$121Food and BeverageIn-kind items and servicesRYBREVANT Drug, Oncology2025
2025-07-30Merck Sharp & Dohme LLC$26Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-07-29Janssen Biotech, Inc.$2,860Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-07-29Novartis Pharmaceuticals Corporation$34Food and BeverageIn-kind items and servicesLUTATHERA Drug, Oncology2025
2025-07-28AstraZeneca Pharmaceuticals LP$31Food and BeverageIn-kind items and servicesTAGRISSO Drug, Oncology2025
2025-07-25Takeda Pharmaceuticals U.S.A., Inc.$20Food and BeverageIn-kind items and servicesICLUSIG Drug, ONCOLOGY2025
2025-07-25Takeda Pharmaceuticals U.S.A., Inc.$4Food and BeverageIn-kind items and servicesICLUSIG Drug, ONCOLOGY2025
2025-07-25Takeda Pharmaceuticals U.S.A., Inc.$1Food and BeverageIn-kind items and servicesNINLARO Drug, ONCOLOGY2025
2025-07-24ABBVIE INC.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVENCLEXTA Drug, ONCOLOGY2025
2025-07-24Janssen Biotech, Inc.$110Food and BeverageIn-kind items and servicesRYBREVANT Drug, Oncology2025
2025-07-24Merck Sharp & Dohme LLC$30Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-07-23Karyopharm Therapeutics Inc.$96Food and BeverageIn-kind items and servicesXPOVIO Drug, Oncology2025
2025-07-22ARRAY BIOPHARMA INC$24Food and BeverageIn-kind items and servicesLORBRENA Drug, ONCOLOGY2025
2025-07-22AstraZeneca Pharmaceuticals LP$22Food and BeverageIn-kind items and servicesIMFINZI Biological, Oncology2025
2025-07-17Incyte Corporation$5,775Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMonjuvi Drug, Oncology2025
2025-07-16Novartis Pharmaceuticals Corporation$4,200Consulting FeeCash or cash equivalentKYMRIAH Drug, Oncology2025
2025-07-16ARRAY BIOPHARMA INC$25Food and BeverageIn-kind items and servicesLORBRENA Drug, ONCOLOGY2025
2025-07-16PFIZER INC.$19Food and BeverageIn-kind items and servicesXTANDI Drug, ONCOLOGY2025
2025-07-14ABBVIE INC.$149Food and BeverageIn-kind items and servicesVENCLEXTA Drug, ONCOLOGY2025
2025-07-14ABBVIE INC.$22Travel and LodgingIn-kind items and servicesVENCLEXTA Drug, ONCOLOGY2025
2025-07-14ABBVIE INC.$19Travel and LodgingIn-kind items and servicesVENCLEXTA Drug, ONCOLOGY2025
2025-07-12Janssen Biotech, Inc.$115Travel and LodgingCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-07-12Janssen Biotech, Inc.$98Travel and LodgingCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-07-12Janssen Biotech, Inc.$47Food and BeverageCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-07-10ABBVIE INC.$600Consulting FeeCash or cash equivalentVENCLEXTA Drug, ONCOLOGY2025
2025-07-10Merck Sharp & Dohme LLC$27Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-07-09Iovance Biotherapeutics, Inc.$28Food and BeverageCash or cash equivalentAmtagvi Drug, Oncology2025
2025-07-09Incyte Corporation$13Food and BeverageCash or cash equivalentMONJUVI Drug, Oncology2025
2025-07-08Rigel Pharmaceuticals, Inc.$22Food and BeverageCash or cash equivalentTAVALISSE Drug, Hematology2025
2025-07-07E.R. Squibb & Sons, L.L.C.$30Food and BeverageCash or cash equivalentOPDIVO Biological, Oncology2025
2025-07-03ABBVIE INC.$14Food and BeverageIn-kind items and servicesVENCLEXTA Drug, ONCOLOGY2025
2025-07-02Janssen Biotech, Inc.$3,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-07-02Janssen Biotech, Inc.$1,650Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-07-02Janssen Biotech, Inc.$880Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRYBREVANT Drug, Oncology2025
2025-07-02Merck Sharp & Dohme LLC$19Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-07-01Genmab U.S., Inc.$26Food and BeverageIn-kind items and servicesEpkinly Drug, Oncology2025
2025-06-30Celgene Corporation$30Food and BeverageCash or cash equivalentREBLOZYL Biological, Hematology2025
2025-06-30Celgene Corporation$0Food and BeverageCash or cash equivalentREBLOZYL Biological, Hematology2025
2025-06-28Incyte Corporation$1,371Travel and LodgingCash or cash equivalentMonjuvi Drug, Oncology2025
2025-06-28Incyte Corporation$303Travel and LodgingCash or cash equivalentMonjuvi Drug, Oncology2025
2025-06-28Incyte Corporation$108Travel and LodgingCash or cash equivalentMonjuvi Drug, Oncology2025
2025-06-28Incyte Corporation$60Food and BeverageCash or cash equivalentMonjuvi Drug, Oncology2025
2025-06-28Incyte Corporation$59Food and BeverageCash or cash equivalentMonjuvi Drug, Oncology2025
2025-06-28Incyte Corporation$29Food and BeverageCash or cash equivalentMonjuvi Drug, Oncology2025
2025-06-28Incyte Corporation$29Food and BeverageCash or cash equivalentMonjuvi Drug, Oncology2025
2025-06-27Incyte Corporation$12Food and BeverageCash or cash equivalentMonjuvi Drug, Oncology2025
2025-06-26Janssen Biotech, Inc.$139Food and BeverageIn-kind items and servicesRYBREVANT Drug, Oncology2025
2025-06-26Integra LifeSciences Corporation$44Food and BeverageIn-kind items and servicesOMNIGRAFT Device, Recon-Skin and Wound2025
2025-06-26Janssen Biotech, Inc.$26Food and BeverageIn-kind items and servicesRYBREVANT Drug, Oncology2025
2025-06-25Janssen Biotech, Inc.$33Food and BeverageIn-kind items and servicesDARZALEX Biological, Oncology2025
2025-06-25Boehringer Ingelheim Pharmaceuticals, Inc.$26Food and BeverageIn-kind items and services2025
2025-06-24Janssen Biotech, Inc.$707Travel and LodgingIn-kind items and servicesRYBREVANT Drug, Oncology2025
2025-06-23SpringWorks Therapeutics, Inc.$27Food and BeverageIn-kind items and servicesGOMEKLI Drug, NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS2025
2025-06-23ABBVIE INC.$16Food and BeverageIn-kind items and servicesIMBRUVICA Drug, ONCOLOGY2025
2025-06-19Eisai Inc.$24Food and BeverageIn-kind items and servicesLenvima Drug, Oncology2025
2025-06-19Lilly USA, LLC$23Food and BeverageIn-kind items and servicesVERZENIO Drug, Oncology2025
2025-06-18GlaxoSmithKline, LLC.$31Food and BeverageIn-kind items and servicesJEMPERLI Biological, ONCOLOGY2025
2025-06-18AstraZeneca Pharmaceuticals LP$23EducationIn-kind items and services2025
2025-06-17Karyopharm Therapeutics Inc.$3,875HonorariaCash or cash equivalentXPOVIO Drug, Oncology2025
2025-06-17Novartis Pharmaceuticals Corporation$2,100Consulting FeeCash or cash equivalent2025
2025-06-17Karyopharm Therapeutics Inc.$218Travel and LodgingCash or cash equivalentXPOVIO Drug, Oncology2025
2025-06-17Karyopharm Therapeutics Inc.$119Food and BeverageIn-kind items and servicesXPOVIO Drug, Oncology2025
2025-06-13Genmab U.S., Inc.$4,160Consulting FeeCash or cash equivalentEpkinly Drug, Oncology2025
2025-06-12Celgene Corporation$26Food and BeverageCash or cash equivalentREBLOZYL Biological, Hematology2025
2025-06-10Merck Sharp & Dohme LLC$34Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025

The latest 200 records of 777.

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-09-25Incyte CorporationSutter Santa Rosa Regional Hospital$3,450A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo2025
2025-05-28Celgene CorporationCPMC-R.K. DAVIES MEDICAL CENTER$1,875Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Regist2025
2025-04-03ABBVIE INC.Sutter Santa Rosa Regional Hospital$15,053A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2025
2025-03-07ABBVIE INC.Sutter Santa Rosa Regional Hospital$6,907M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combinatio2025
2025-03-06Incyte CorporationSutter Santa Rosa Regional Hospital$431A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo2025
2025-02-06ABBVIE INC.Sutter Santa Rosa Regional Hospital$18,044M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combinatio2025
2025-01-01Novartis Pharmaceuticals CorporationALTA BATES SUMMIT MEDICAL CENTER$78,235A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase 2025
2024-12-30ABBVIE INC.CPMC-R.K. DAVIES MEDICAL CENTER$5,821A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2024
2024-12-05ABBVIE INC.CPMC-R.K. DAVIES MEDICAL CENTER$23,765A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2024
2024-11-07ABBVIE INC.CPMC-R.K. DAVIES MEDICAL CENTER$5,665A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compar2024
2024-10-03ABBVIE INC.CPMC-R.K. DAVIES MEDICAL CENTER$12,771A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2024
2024-09-11Celgene CorporationCpmc - Mission Bernal Campus$1,500Celgene Connect Myeloid Disease Registry2024
2024-09-05E.R. Squibb & Sons, L.L.C.ALTA BATES SUMMIT MEDICAL CENTER$375Connect MM The Multiple Myeloma Disease Registry2024
2024-09-04ABBVIE INC.CPMC-R.K. DAVIES MEDICAL CENTER$17,267Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participa2024
2024-09-04ABBVIE INC.CPMC-R.K. DAVIES MEDICAL CENTER$22,011A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2024
2024-08-02ABBVIE INC.CPMC-R.K. DAVIES MEDICAL CENTER$7,227A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2024
2024-07-05ABBVIE INC.CPMC-R.K. DAVIES MEDICAL CENTER$32,961A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C2024
2024-06-06ABBVIE INC.Sutter Santa Rosa Regional Hospital$17,267Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse2024
2024-05-28Novartis Pharmaceuticals CorporationALTA BATES SUMMIT MEDICAL CENTER$135,760A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase 2024
2024-05-15Celgene CorporationCpmc - Mission Bernal Campus$375The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment2024
2024-03-07Incyte CorporationCpmc - Mission Bernal Campus$3,885A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo2024
2024-03-07ABBVIE INC.CPMC-R.K. DAVIES MEDICAL CENTER$17,267A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with 2024
2024-01-31Celgene CorporationCpmc - Mission Bernal Campus$375The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment2024
2024-01-18Incyte CorporationCpmc - Mission Bernal Campus$3,450A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants2024
2023-11-10Celgene CorporationCpmc Van Ness Campus$546A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single2023
2023-08-09Incyte CorporationSUTTER SANTA ROSA REGIONAL HOSPITAL$500A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants2023
2023-06-07Celgene CorporationALTA BATES SUMMIT MEDICAL CENTER$375Connect MM- The Multiple Myeloma Disease Registry2023
2023-05-23Celgene CorporationALTA BATES SUMMIT MEDICAL CENTER$2,250A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single2023
2023-03-29Incyte CorporationSUTTER SANTA ROSA REGIONAL HOSPITAL$1,350A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants2023
2023-03-23Incyte CorporationSUTTER SANTA ROSA REGIONAL HOSPITAL$1,350A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo2023
2023-01-18Celgene CorporationCpmc Van Ness Campus$2,625Connect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (A2023
2022-12-28Incyte CorporationCpmc-R.K. Davies Medical Center$1,500A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo2022
2022-11-03Incyte CorporationCpmc-R.K. Davies Medical Center$18,750A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants2022
2022-10-20Incyte CorporationCpmc-R.K. Davies Medical Center$1,550A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants2022
2022-09-15Incyte CorporationCpmc-R.K. Davies Medical Center$750A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo2022
2022-09-13Celgene CorporationALTA BATES SUMMIT MEDICAL CENTER$375Connect MM- The Multiple Myeloma Disease Registry2022
2022-08-30Incyte CorporationCpmc-R.K. Davies Medical Center$18,750A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo2022
2022-07-27Celgene CorporationCpmc Van Ness Campus$2,250Connect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (A2022
2022-01-21Celgene CorporationCpmc Van Ness Campus$910A Phase 3B Randomized Study of Lenalidomide (CC-502022
2022-01-20E.R. Squibb & Sons, L.L.C.Cpmc-R.K. Davies Medical Center$19,170A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previo2022
2021-11-23Celgene CorporationALTA BATES SUMMIT MEDICAL CENTER$1,875Connect MM- The Multiple Myeloma Disease Registry2021
2021-08-04Celgene CorporationCpmc Van Ness Campus$3,125Connect MDS/AML2021
2021-02-12Celgene CorporationALTA BATES SUMMIT MEDICAL CENTER$3,000A Phase 3B Randomized Study of Lenalidomide (CC-502021
2020-12-23Incyte CorporationSt. Lukes Hospital$4,500A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With2020
2020-12-23Incyte CorporationSt. Lukes Hospital$1,500A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With2020
2020-12-23Incyte CorporationSt. Lukes Hospital$1,000A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With2020
2020-12-16Celgene CorporationSt. Lukes Hospital$1,500Celgene - Connect MDS/AML2020
2020-12-15Celgene CorporationALTA BATES SUMMIT MEDICAL CENTER$182A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single2020
2020-07-03Celgene CorporationResearch & Education Institute Of Alta Bates Summit Med Cen$500A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single2020
2020-02-17Celgene CorporationSUTTER SANTA ROSA REGIONAL HOSPITAL$3,375Celgene - Connect MDS/AML2020
2020-02-14Celgene CorporationAlta Bates Summit Medical Center Brachytherapy Center$182A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single2020
2020-02-11Celgene CorporationAlta Bates Summit Medical Center Summit Campus$1,145Celgene - Connect MM2020
2020-01-21E.R. Squibb & Sons, L.L.C.ALTA BATES SUMMIT MEDICAL CENTER$900A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previo2020
2019-11-11Incyte CorporationCALIFORNIA PACIFIC MEDICAL CENTER$8,500A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-10-15Celgene CorporationALTA BATES SUMMIT MEDICAL CENTER$750Connect MM- The Multiple Myeloma Disease Registry (OS002982)2019
2019-10-01Celgene CorporationSUTTER EAST BAY HOSPITALS$1,500Connect MM- The Multiple Myeloma Disease Registry (OS002982)2019
2019-09-06Celgene CorporationSUTTER BAY HOSPITALS DBAJordan Research and Education$1,326A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single2019
2019-08-08Incyte CorporationALTA BATES MED CTR$31A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$0A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$58A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$76A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$3A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$76A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$76A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$47A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$30A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$20A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$40A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$5A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$3A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$6A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$6A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$2A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$47A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-08-08Incyte CorporationALTA BATES MED CTR$36A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With2019
2019-07-23E.R. Squibb & Sons, L.L.C.ALTA BATES SUMMIT MEDICAL CENTER$3,888A Phase 3, Randomized, Open Label Trial of LenalidomideDexamethasone With or Without Elotuzumab in Subjects With Previou2019
2019-05-29Celgene CorporationALTA BATES SUMMIT MEDICAL CENTER$750Celgene - Connect MM2019
2019-02-22Celgene CorporationSUTTER SANTA ROSA REGIONAL HOSPITAL$3,375Celgene - Connect MDSAML2019
2019-01-02Celgene CorporationALTA BATES SUMMIT MEDICAL CENTER$750Celgene - Connect CLL2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Alameda CountyBerkeley city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Berkeley, CA, county Alameda County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Berkeley, CA
County
Alameda County, CA
State
California
Population B01003120,2571,649,47339,287,377
Population, 2020 census P1124,3211,682,35339,538,223
Median age B0100233.239.037.9
Under 18 B0100112.7%19.8%22.0%
65 and over B0100116.7%15.4%15.7%
Households B1100147,135598,24613,548,091
Foreign born B0500221.1%34.7%27.0%
Median household income B19013$108,092$129,367$99,122
Median family income B19113$202,712$159,585$113,346
Per capita income B19301$69,534$65,862$49,513
Poverty rate B1700117.3%9.2%12.0%
Unemployment rate B230255.6%5.4%6.6%
Civilian labor force B2302564,277908,99520,068,466
Mean commute (minutes) B0801327.831.028.7
Bachelor's degree or higher B1500374.9%52.2%37.1%
Housing units B2500153,145637,21214,644,735
Owner-occupied B2500344.2%54.4%55.9%
Renters B2500355.8%45.6%44.1%
Median home value B25077$1,413,900$1,090,100$734,700
Median gross rent B25064$2,133$2,357$2,036
White, not Hispanic B0300249.9%27.4%33.8%
Black B030027.7%9.3%5.2%
Hispanic or Latino B0300212.8%23.4%40.2%
Asian B0300220.4%32.7%15.3%
American Indian and Alaska Native B030020.1%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Berkeley, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.